Our planet

As we grow our business to bring innovative medicines and over the counter healthcare products to people around the world, we are committed to reducing our environmental impact across all areas of our business.

At GSK Nigeria, we set out specific public commitments that together reflect the breadth of our contribution towards addressing the UN’s Global Goals for Sustainable Development while delivering sustainable, improved financial returns for our shareholders. We report progress in SDG 3, 5, 10, 12, 13 and 17 against these commitments each year in our Annual Report.


How we support the SDGs


Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml)


SDG3 – Good Health and Wellbeing 

The primary way in which we support SDG 3 is by using our science and technology to address health needs, and by making our products affordable and available. Using our science and technology to address health needs. The biggest impact that we can have on health is to successfully research and develop innovative products. Through our innovation we aim to develop differentiated, high quality, needed medicines, vaccines and consumer products to improve health. We also have a responsibility to impact global health, particularly in the prevention and treatment of infectious diseases where we have world-leading scientific expertise. We support global efforts to reduce the burden of HIV/AIDS, TB, malaria and neglected tropical diseases (NTDs), which disproportionately affect people in developing countries, through a range of R&D initiatives. In 2018, GSK topped the Access to Medicines Index for the sixth consecutive time, with specific recognition for having the largest proportion of our R&D pipeline dedicated to priority diseases.

Example of our work supporting SDG3 include:

Malaria: Our new malaria treatment tafenoquine (Krintafel/Kozenis) is a single dose radical cure for P. vivax malaria, developed in partnership with the Medicines for Malaria Venture (MMV) and the first new treatment for this type of relapsing malaria in over 60 years. Our malaria vaccine RTS,S (Mosquirix), which aims to protect children from P. falciparum malaria, responsible for most malarial deaths worldwide, is moving into a World Health Organisation (WHO)-led pilot implementation programme in three countries in Africa- Ghana, Kenya and Malawi. We also have clinical trials underway for a next-generation malaria vaccine.

Access to vaccines: GSK has one of the most diverse vaccines portfolios in the industry, ranging from traditional childhood vaccines to newer vaccines with few other suppliers. We reserve our lowest vaccines prices for organisations such as Gavi, the Vaccine Alliance, delivering them millions of doses each year.

Access to NTD treatment: We have committed to donate approximately 600 million albendazole treatments to WHO each year until lymphatic filariasis (LF) is eliminated as a public health problem globally (8.5 billion donated over the last two decades). We have also committed to donate up to 400 million albendazole treatments to WHO through to the end of 2020 for deworming programmes for school aged children.

Save the Children partnership interventions: Our ten-year, multi-faceted partnership with Save the Children to help reduce the number of children dying from preventable and treatable diseases has reached millions of children under five since 2013, in over 45 countries, with interventions including widening immunisation coverage, accelerating access to treatments and strengthening healthcare systems. It has also supported the development and delivery of Umbipro, our chlorhexidine gel to prevent umbilical cord infections.

Training frontline health workers: We have a longstanding investment in training frontline health workers in developing countries, in partnership with Amref Health Africa, CARE International and Save the Children.


Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml)

SDG 5 and 10: Gender Inequality & Reduced inequalities

We aim for over 37% female representation in our senior roles globally by 2022. We have a programme to support development and career progression for high-performing female managers, recruit and support women early in their careers and report progress on the proportion of women in SVP/VP and management level roles. Our female senior executive population is increasing as long-running programmes to create a strong female pipeline deliver results.

In Nigeria, GSK relaunched the Women's Leadership Initiative (WLI) to promote and retain women by improving on 3 strategic focuses:  growth, development, engagement, inclusion and diversity. This is consistent with our position as a modern employer to support diversity and inclusion. In 2019, in celebration of International Women’s Day, GSK Nigeria held a forum hosted by a panel of male and female senior executive from various globally recognized industries. The session sparked an open dialogue on the female navigation journey and challenge route to leadership, issues of gender pay gap and how to change the narrative.

At GSK, maintaining balance is viewed as essential for economies, businesses and communities to thrive; recognizing that 'Balance' is not a women's issue, but a business issue. The race is on for the gender-balanced boardroom, a gender-balanced government, gender-balanced media coverage, a gender-balance of employees, more gender-balance in wealth, and gender-balanced sports coverage.


Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml)

SDG 12 & 13 – Responsible Consumption & Production & Climate Action

Our goal is for all our waste to be repurposed for beneficial uses by 2030, avoiding harmful environmental impacts from landfill and keeping materials in circulation for use in new products. We have initiatives in place to reduce energy consumption, water-use reduction and waste management. Our activities are as follows:


Our outstanding energy conservation initiatives resulted in 4% reductions in energy consumption over target in 2019. Our plan to improve Overall Equipment Effectiveness (OEE) will further help reduce energy usage/carbon emission. GSK recorded an improvement in energy use in 2019 versus 2018 FY actual with 2.6millionkWh of energy consumed in 2019 versus 2.7million kWh in 2018.

We also implemented the following key actions to reduce energy usage:

  • Heating, Ventilation and Air Conditioning (HVAC) integration with the Building Management System (BMS) was integral to the optimisation of energy use for general conditioning of production suites, meeting quality standards.
  • Responsible use of skylights in the warehouse during day operations.
  • Utilisation of energy lights with motion sensor in strategic locations
  • Improvement in Overall Equipment Effectiveness (OEE), spurring timely meeting of production targets and energy conservation on shutdown days.



For our water-use reductions, we over-achieved our consumption target with an 18% reduction compared to consumption in 2017.


GSK applies the principles of the internationally recognized Waste Management to best manage and protect the environment such as waste avoidance, reduction of waste; resource recovery, reuse and recycling; and disposal in an environmentally responsible way. In 2017, we achieved a zero-landfill status on waste management.

This is significant improvement in comparison to 2016 where we reduced our solid waste to landfill by 50%. We achieved this through diligent waste management by diverting OTC blister wastes to Geo-cycle (Lafarge) for reuse in their operations.

Additionally, as of March of 2017 we completed a 100% milestone in our Environment Hazard Assessment Concertation Program (EHAC). The objective of this programme is to assess the potential environmental impact associated with wastewater discharges from GSK manufacturing sites before discharge into receiving streams or waterbodies.

As part of this process, we monitor our discharge to the municipal treatment plant through weekly laboratory analysis by a government accredited laboratory. We are now at a sustainability stage of improving our processes prior to the NPI launch (New Product launch) to ensure we maintain a cleaner environment by monitoring through strict change controls, newly introduced chemicals that could impact the environment.


As part of our commitment to improving our safety culture, we implemented an aggressive ZAP reporting through a weekly ‘Stop for safety program’, in which staff are educated on relevant safety and caution topics identified periodically. We achieved a Zero RIIR (Reportable Incident Injury Rate) in 2019, over-achieving our site target of 0.49 by leveraging on ZAP reporting (Zero Accident Promotion).


Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml)

SDG Goal 17: Partnerships for theGoals

We form diverse partnerships across academia and charitable institutions, in pursuit of ground-breaking innovation. Our global health work in support of SDG3 in Nigeria has been done in partnership with many organisations such as Save the Children and SOS Children’s Village. We believe partnerships across companies, funders, governments and development NGOs spread risks and draw on each parties’ unique expertise, offering the best route for global health discoveries to be incentivised, developed and brought to patients as rapidly as possible.